To amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships.

Bill: 117-hr-7658
Sponsor: full_name: Rep. O'Halleran, Tom [D-AZ-1]
Introduced: 2022-05-03
Policy area: Health
Latest action: action_date: 2022-05-03
text: Referred to the House Committee on Energy and Commerce.

Summaries:
action_date: 2022-05-03
action_desc: Introduced in House
text: <p>This bill reauthorizes through FY2027 the Food and Drug Administration's Critical Path Public-Private Partnerships, which support medical product innovation, development, and safety.</p>

tv_txt: I 117th CONGRESS 2d Session H. R. 7658 IN THE HOUSE OF REPRESENTATIVES May 3, 2022 Mr. O'Halleran (for himself and Mrs. Lesko ) introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships.

1. Reauthorization of the Critical Path Public-Private Partnerships Section 566(f) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360bbb–5(f) ) is amended by striking $6,000,000 for each of fiscal years 2018 through 2022 and inserting $10,000,000 for each of fiscal years 2023 through 2027 .